| 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis S Jin, D Cojocari, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ... Clinical Cancer Research 26 (13), 3371-3383, 2020 | 163 | 2020 |
| A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients D Rodenhizer, E Gaude, D Cojocari, R Mahadevan, C Frezza, ... Nature materials 15 (2), 227-234, 2016 | 154 | 2016 |
| Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium EO Pettersen, P Ebbesen, RG Gieling, KJ Williams, L Dubois, P Lambin, ... Journal of enzyme inhibition and medicinal chemistry 30 (5), 689-721, 2015 | 135 | 2015 |
| PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ... Nature cell biology 18 (7), 803-813, 2016 | 133 | 2016 |
| AMPK regulates metabolism and survival in response to ionizing radiation VE Zannella, D Cojocari, S Hilgendorf, RN Vellanki, S Chung, ... Radiotherapy and Oncology 99 (3), 293-299, 2011 | 77 | 2011 |
| The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia MBE Schaaf, D Cojocari, TG Keulers, B Jutten, MH Starmans, MC de Jong, ... Radiotherapy and Oncology 108 (3), 529-534, 2013 | 61 | 2013 |
| New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia D Cojocari, RN Vellanki, B Sit, D Uehling, M Koritzinsky, BG Wouters Radiotherapy and Oncology 108 (3), 541-547, 2013 | 57 | 2013 |
| Quantitative visualization of hypoxia and proliferation gradients within histological tissue sections M Zaidi, F Fu, D Cojocari, TD McKee, BG Wouters Frontiers in Bioengineering and Biotechnology 7, 397, 2019 | 48 | 2019 |
| Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment? JD Leverson, D Cojocari Frontiers in Oncology 8, 458, 2018 | 44 | 2018 |
| A three-dimensional engineered heterogeneous tumor model for assessing cellular environment and response D Rodenhizer, T Dean, B Xu, D Cojocari, AP McGuigan Nature protocols 13 (9), 1917-1957, 2018 | 42 | 2018 |
| Development of TRACER: tissue roll for analysis of cellular environment and response D Rodenhizer, D Cojocari, BG Wouters, AP McGuigan Biofabrication 8 (4), 045008, 2016 | 36 | 2016 |
| Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia D Cojocari, BN Smith, JJ Purkal, MP Arrate, JD Huska, Y Xiao, A Gorska, ... Haematologica 107 (4), 825, 2021 | 31 | 2021 |
| Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 29 | 2018 |
| Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients J Yuda, C Will, DC Phillips, L Abraham, C Alvey, A Avigdor, W Buck, ... Communications Medicine 3 (1), 154, 2023 | 26 | 2023 |
| Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia S Cathelin, D Sharon, A Subedi, D Cojocari, DC Phillips, JD Leverson, ... Leukemia 36 (3), 869-872, 2022 | 14 | 2022 |
| Pevonedistat, a Nedd-8 activating enzyme inhibitor, upregulates NOXA to increase effectiveness of azacitidine and venetoclax in preclinical models of acute myelogenous leukemia BN Smith, D Cojocari, JJ Purkal, M Arrate, HE Ramsey, JD Leverson, ... Blood 134, 1380, 2019 | 4 | 2019 |
| 5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis D Cojocari, S Jin, JJ Purkal, R Popovic, NN Talaty, Y Xiao, LR Solomon, ... Blood 132, 2644, 2018 | 4 | 2018 |
| Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma J Zhang, Q Liu, D Cojocari, M Zaidi, T McKee, N Radulovich, MS Tsao, ... Cancer Research 78 (13_Supplement), 2443-2443, 2018 | 3 | 2018 |
| Therapeutic targeting of tumour hypoxia through the unfolded protein response and autophagy pathways D Cojocari University of Toronto (Canada), 2017 | 1 | 2017 |
| Abstract SY31-02: Determinants of hypoxia in pancreatic cancer and identification of ULK1 as a potential therapeutic target J Zhang, D Cojocari, R Cairns, M Koritzinsky, BG Wouters Cancer Research 83 (7_Supplement), SY31-02-SY31-02, 2023 | | 2023 |
Bradly WoutersPrincess Margaret Cancer Centre, University Health Network, University of Toronto確認したメール アドレス: uhn.ca